中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2012年
30期
23-25
,共3页
郭丰义%霍振洪%沈玉莲%张大艳
郭豐義%霍振洪%瀋玉蓮%張大豔
곽봉의%곽진홍%침옥련%장대염
高血压%缓激肽%C反应蛋白质%阿利吉仑
高血壓%緩激肽%C反應蛋白質%阿利吉崙
고혈압%완격태%C반응단백질%아리길륜
Hypertension%Bradykinin%C-reactive proteins%Aliskiren
目的 研究新型非肽类肾素抑制剂阿利吉仑对高血压患者缓激肽(BK)和高敏C反应蛋白(hs-CRP)的影响.方法 选取门诊进行治疗的轻、中度原发性高血压患者80例.按随机数字表法分为雷米普利组、阿利吉仑75 mg/d组、阿利吉仑150 mg/d组、阿利吉仑300 mg/d组,每组20例,分别接受雷米普利5 mg/d,阿利吉仑75、150及300 mg/d治疗.采用酶联免疫吸附试验法检测hs-CRP水平,采用放射免疫法检测BK水平.结果 阿利吉仑75 mg/d组、阿利吉仑150 mg/d组、阿利吉仑300 mg/d组治疗后BK及hs-CRP水平分别为(5.06±1.61)、(5.05±1.87)、(5.27±1.39)μg/L和(0.38±0.11)、(0.25±0.05)、(0.33±0.11)mg/L,均显著低于雷米普利组[(7.12±1.12)μg/L、(0.49±0.19) mg/L] (P值均＜0.05)；阿利吉仑各剂量组治疗后收缩压、舒张压与雷米普利组治疗后比较差异无统计学意义(P值均＞ 0.05).结论 阿利吉仑具有很好的降压效果,且不会引起BK及hs-CRP的增高.
目的 研究新型非肽類腎素抑製劑阿利吉崙對高血壓患者緩激肽(BK)和高敏C反應蛋白(hs-CRP)的影響.方法 選取門診進行治療的輕、中度原髮性高血壓患者80例.按隨機數字錶法分為雷米普利組、阿利吉崙75 mg/d組、阿利吉崙150 mg/d組、阿利吉崙300 mg/d組,每組20例,分彆接受雷米普利5 mg/d,阿利吉崙75、150及300 mg/d治療.採用酶聯免疫吸附試驗法檢測hs-CRP水平,採用放射免疫法檢測BK水平.結果 阿利吉崙75 mg/d組、阿利吉崙150 mg/d組、阿利吉崙300 mg/d組治療後BK及hs-CRP水平分彆為(5.06±1.61)、(5.05±1.87)、(5.27±1.39)μg/L和(0.38±0.11)、(0.25±0.05)、(0.33±0.11)mg/L,均顯著低于雷米普利組[(7.12±1.12)μg/L、(0.49±0.19) mg/L] (P值均＜0.05)；阿利吉崙各劑量組治療後收縮壓、舒張壓與雷米普利組治療後比較差異無統計學意義(P值均＞ 0.05).結論 阿利吉崙具有很好的降壓效果,且不會引起BK及hs-CRP的增高.
목적 연구신형비태류신소억제제아리길륜대고혈압환자완격태(BK)화고민C반응단백(hs-CRP)적영향.방법 선취문진진행치료적경、중도원발성고혈압환자80례.안수궤수자표법분위뢰미보리조、아리길륜75 mg/d조、아리길륜150 mg/d조、아리길륜300 mg/d조,매조20례,분별접수뢰미보리5 mg/d,아리길륜75、150급300 mg/d치료.채용매련면역흡부시험법검측hs-CRP수평,채용방사면역법검측BK수평.결과 아리길륜75 mg/d조、아리길륜150 mg/d조、아리길륜300 mg/d조치료후BK급hs-CRP수평분별위(5.06±1.61)、(5.05±1.87)、(5.27±1.39)μg/L화(0.38±0.11)、(0.25±0.05)、(0.33±0.11)mg/L,균현저저우뢰미보리조[(7.12±1.12)μg/L、(0.49±0.19) mg/L] (P치균＜0.05)；아리길륜각제량조치료후수축압、서장압여뢰미보리조치료후비교차이무통계학의의(P치균＞ 0.05).결론 아리길륜구유흔호적강압효과,차불회인기BK급hs-CRP적증고.
Objective To explore the value of a novel non-peptide renin inhibitor aliskiren on hypertension patients,and analyze the change of bradykinin (BK) and high sensitive C-reactive protein (hs-CRP).Methods Eighty patients with mild to moderate hypertension were selected.Patients were randomized divided into ramipril group,aliskiren 75 mg/d group,aliskiren 150 mg/d group,aliskiren 300 mg/d group with 20 cases each by random digits table method and received the following types of intervention:ramipril 5 mg/d,aliskiren 75 mg/d,aliskiren 150 mg/d and aliskiren 300 mg/d.Enzyme-linked immunosorbent assay method was used for detecting hs-CRP.Radioimmunoassay method was used for detecting BK.Results After treatment,the levels of BK and hs-CRP in aliskiren 75 mg/d group,aliskiren 150 mg/d group and aliskiren 300 mg/d group [(5.06 ± 1.61),(5.05 ± 1.87),(5.27 ± 1.39) μg/L and (0.38 ± 0.11 ),(0.25 ± 0.05),(0.33 ± 0.11 ) mg/L] were significantly lower than those in ramipril group [ (7.12 ± 1.12) μ g/L,(0.49 ± 0.19) mg/L ] (P＜0.05 ).After treatment,the levels of SBP and DBP had no significant difference among the four groups (P＞0.05).Conclusion Aliskiren has a very good effect in decreasing blood pressure and does not cause the levels of BK and hs-CRP increasing.
